Æterna Zentaris gets positive data from phase-2 study of targeted cytotoxic peptide conjugate, AEZS-108
Thursday, November 26, 2009 13:00 IST Québec City, Canada
Æterna Zentaris Inc, a global biopharmaceutical company focused on endocrine therapy and oncology, announced positive efficacy data from a phase-2 study with its targeted cytotoxic peptide conjugate